SwitchPoint Financial Planning LLC Acquires Shares of 307 Eli Lilly and Company $LLY

SwitchPoint Financial Planning LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, Holdings Channel.com reports. The fund acquired 307 shares of the company’s stock, valued at approximately $240,000.

A number of other large investors have also recently made changes to their positions in the business. Ferguson Shapiro LLC bought a new position in shares of Eli Lilly and Company in the second quarter valued at $1,152,000. Mizuho Markets Cayman LP bought a new position in shares of Eli Lilly and Company in the second quarter valued at $3,037,000. Zhang Financial LLC lifted its position in shares of Eli Lilly and Company by 0.7% during the second quarter. Zhang Financial LLC now owns 2,580 shares of the company’s stock valued at $2,011,000 after purchasing an additional 17 shares in the last quarter. New York Life Investment Management LLC lifted its position in shares of Eli Lilly and Company by 1.6% during the second quarter. New York Life Investment Management LLC now owns 107,958 shares of the company’s stock valued at $84,156,000 after purchasing an additional 1,731 shares in the last quarter. Finally, Private Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 4.6% during the second quarter. Private Wealth Partners LLC now owns 5,637 shares of the company’s stock valued at $4,394,000 after purchasing an additional 250 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $821.60 on Wednesday. The firm has a market cap of $777.61 billion, a price-to-earnings ratio of 53.70, a P/E/G ratio of 1.23 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm’s 50-day simple moving average is $772.90 and its two-hundred day simple moving average is $769.79.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 39.22%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. Guggenheim reissued a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. UBS Group dropped their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. JPMorgan Chase & Co. dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.